The Wall Street Journal reports that Johnson & Johnson’s fourth-quarter earnings fell 89% following settlements for misrepresenting the risks and benefits of Risperdal, its once top-selling drug.
Read more Discuss →
The Wall Street Journal reports that Johnson & Johnson’s fourth-quarter earnings fell 89% following settlements for misrepresenting the risks and benefits of Risperdal, its once top-selling drug.
Read more Discuss →
***
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
***
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.